Venetoclax (Venclyxto®) accepted for restricted use within NHS Scotland in combination with obinutuzumab for treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)

Restricted for use in patients without del (17p)/TP53 mutation who are not fit to receive fludarabine, cyclophosphamide and rituximab chemo-immunotherapy; and patients with del (17p)/TP53 mutation.

Scottish Medicines Consortium